Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap

Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month.

The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption.

Orthocell has secured exclusive distributorships for Alberta and British Columbia, and expects to make further appointments across other provinces to ensure broad coverage in the $113 million market.

Peripheral Nerve Regeneration

Orthocell manufactures Remplir in Perth for use in surgical settings to improve the regeneration of severed or severely-damaged peripheral nerves.

The wrap can assist in restoring function and sensation by providing compression-free protection to the nerve, thereby generating an ideal micro-environment to promote healing.

Remplir received a medical device licence from Health Canada in April and Orthocell is targeting first sales into the region during the December quarter.

The company estimates the global nerve repair market is worth more than $5.3 billion, with around 2 million peripheral nerve repair surgeries performed each year.

Next-Generation Solution

“Securing our first Canadian distributor is a major step in accelerating Remplir’s international growth and building its profile as a next-generation nerve repair solution,” chief executive officer Paul Anderson said.

“Our existing US Marketing and Medical Education teams are ideally placed to oversee our Canadian market entry given the significant crossover between jurisdictions with many surgeons operating in both countries.

Orthocell anticipates early surgical applications of Remplir to begin before year end.

With approximately $27.5m in cash and no debt, Orthocell is in an excellent position to drive Remplir’s rapid adoption and deliver a step change in revenue during financial year 2026.

A rollout to the $2.43 billion US market continues to build momentum, with the company’s in-country agents working with local distributors to secure hospital approvals and onboard surgeons.